TRIPS from Doha to Cancún . . . to Ottawa: global developments in access to treatment and Canada’s Bill C-56 — HIV/AIDS Policy & Law Review 8(3)

In November 2003, Canada introduced legislation to amend the Patent Act so that manufacturers could obtain licences to make generic versions of patented pharmaceutical products for export to countries lacking sufficient capacity to produce their own. This article provides an overview of recent global developments leading up to Canada’s initiative, as well as an analysis of Bill C-56 itself.

This entry was posted in English, French, Journal Articles, Publications. Publication Topics: . Bookmark the permalink. Both comments and trackbacks are currently closed.
Doc Type